“Driver” mutations in three genes (Janus kinase (JAK)2, calreticulin (CALR) and myeloproliferative leukemia virus oncogene (MPL)) that activate the JAK2 signaling pathway have been detected in MPN. This evidence concerns the gene CALR and myeloproliferative disorder.